IMpassion031: Results from a phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer

First-line nivolumab + ipilimumab combined with 2 cycles of platinum-based chemotherapy vs 4 cycles of chemo in advanced non-small cell lung cancer: Patient-reported outcomes from CheckMate 9LA

Current state of frontline immunotherapy options in the treatment of mNSCLC and the effect of COVID-19 pandemic on lung cancer management

Clinical considerations of melanoma treatment in 2020

Evolving treatment paradigms for Head and Neck Squamous Cell Carcinoma

Nivolumab plus chemotherapy versus chemo as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: First results of the checkmate 649 study

MONARCH-E trial: Abemaciclib reduces recurrence in HR+ high risk early breast cancer

Triple negative breast cancer highlights in ESMO 2020

Overall survival results from SOLAR-1, a phase III study of alpelisib + fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration

Estimation of European cancer burden for the year 2020

Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

An international randomized trial, comparing post-operative conformal radiotherapy to no PORT, in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement. Primary end-point analysis of Lung ART NCT00410683

KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study

COVID-19 and cancer management